

Substitute for form 1449

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**



Application No. 09/649,527

Applicant: Semple, et al

Filing Date: 08/28/2000

Title: Compositions for Stimulating
Cytokine Secretion and Inducing
an Immune Response

Page 1 of 2

U.S. PATENT DOCUMENTS

Examiners Initials	U S Patent No.	Name of Persons or applicant	Date of Publication of Cited Document
W	5,552,155	Bailey, et al.	09-03-1996
W	5,264,618	Felgner, et al.	11-23-1993
W	5,595,756	Baily, et al	01-21-1997
W	5,264,618	Felgner, et al.	11-23-1993

NON-US PATENTS


Examiner's Initials	Patent No.	Name of Persons or applicant	Date of Publication of Cited Document
W	WO 94/05333	ISIS Pharmaceuticals, Inc.	03-17-1994
W	WO 97/07784	Board of Regents, The University of Texas System	03-06-1997
W	WO 96/18372	Genzyme Corporation	06-20-1996
W	WO 97/46223	Genzyme Corporation	12-11-1997
W	WO 95/27478	The Liposome Company	10-19-1995
W	WO 94/22468	Anti-Cancer, Inc.	10-13-1994

Dale 3/20/02

RECEIVED

JAN 16 2001

Page 2 of 2



TECH CENTER 1600/2900

DR	WO 97/46671	University of British Columbia	12-11-1997
	WO 96/40964	Inex Pharmaceuticals Corporation	12-19-1996
	WO 96/10391	The University of British Columbia	04-11-1996
DR	WO 96/10390	Inex Pharmaceuticals Corp.	04-11-1996

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner's Initial	
DR	OLIVER ZELPHATI, FRANCIS C. SZOKA JR., Liposomes as a carrier for intracellular delivery of antisense oligonucleotides: a real or magic bullet?; Journal of Controlled Release 41 (1996) 99-119.

Examiner Signature

Dahn

Date Considered

3/20/02

Please type a plus sign (+) inside this box

PTO/SB/08A (10-96)
Approved for use through 10/31/99, OMB 0651-0031
Trademark Office: U.S. DEPARTMENT OF COMMERCE
Information unless it contains a valid OMB control number.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Shee

1

Complete if Known

Application Number	09/649,527
Filing Date	August 28, 2000
First Named Inventor	Semple, et al.
Group Art Unit	
Examiner Name	
Attorney Docket Number	INEXP006US

MAR 2 2 2001

RECEIVED

U.S. PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS

Examiner
Signature

Am

Date
Considered

3/20/02

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



Att. #6

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Application No: 09/649,527
Filing Date: 08/26/2000
First Named Inventor: Semple, et al.
Group Art Unit: 1615
Examiner Name:
Attorney Docket No.: INEX.P-006

ADD 64 2001

RECEIVED

Page 1 of 3

FOREIGN PATENT DOCUMENTS

Dahr

3/20/20

Examiner's
Initials

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

PA
MAURER NORBERT ET AL: "Lipid-based systems for the intracellular delivery of genetic drugs." MOLECULAR MEMBRANE BIOLOGY, vol. 16, no. 1, January 1999 (1999-01), pages 129-140, XP000982197 ISSN: 0968-7688 the whole document

P
MEYER OLIVIER ET AL: "Cationic liposomes coated with polyethylene glycol as carriers for oligonucleotides." JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 273, no. 25, 19 June 1998 (1998-06-19), pages 15621-15627, XP002160291 ISSN: 0021-9258 the whole document

P
BOGGS R T ET AL: "CHARACTERIZATION AND MODULATION OF IMMUNE STIMULATION BY MODIFIED OLIGONUCLEOTIDES" ANTISENSE & NUCLEIC ACID DRUG DEVELOPMENT, US, MARY ANN LIEBERT, INC., NEW YORK, vol. 7, 1 October 1997 (1997-10-01), pages 461-471, XP002053418 ISSN: 1087-2906 cited in the application the whole document

J
CHU R S ET AL: "CPG OLIGODEOXYNUCLEOTIDES ACT AS ADJUVANTS THAT SWITCH ON T HELPER 1 (TH1) IMMUNITY" JOURNAL OF EXPERIMENTAL MEDICINE, JP, TOKYO, vol. 186, no. 10, 1 November 1997 (1997-11-01), pages 1623-1631, XP002910130 ISSN: 0022-1007 the whole document

R
BRAMSON JONATHAN L ET AL: "Intravenous administration of stabilized antisense lipid particles (SALP) leads to activation and expansion of liver natural killer cells."

ANTISENSE & NUCLEIC ACID DRUG DEVELOPMENT, vol. 10, no. 3, June 2000 (2000-06), pages 217-224, XP002160292

ISSN: 1087-2906

the whole document

W
WHITMORE M ET AL: "LPD lipopolyplex initiates a potent cytokine response and inhibits tumor growth."

GENE THERAPY, vol. 6, no. 11, November 1999 (1999-11), pages 1867-1875, XP000982147

ISSN: 0969-7128

cited in the application

the whole document

This Information Disclosure Citation List is being submitted as a substitute for Form PTO-1449. The Examiner is requested to place his or her initials on the lines adjacent to the citations to indicate that the reference has been considered. The Examiner is further requested to fill in his or her name and the date the information was considered in blocks at the bottom of this substitute for Form PTO-1449.

Examiner *Am* Date Considered 3/20/02